Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
收藏数据链接：
官方服务：
资源简介：
<b>Table S1 </b> <b>Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching </b> <b> </b> <b>Table S2 </b> <b>Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching</b> <b> </b> <b>Table S3 </b> <b>Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49%</b>
提供机构：
Future Science Group创建时间：
2022-05-03
